Abstract
Response of cutaneous T-cell lymphoma (CTCL) to systemic chemotherapy is unsatisfactory: despite an initially high response rate (RR), duration is always short-lived. To investigate the capability of a third-generation regimen including idarubicin in improving RR and response duration in CTCL patients. Twenty-five patients with advanced CTCL (stages IIB and IV) were treated with a 12-week polychemotherapeutic regimen (VICOP-B), which foresees the use of idarubicin in association with etoposide, cyclophosphamide, vincristine, prednisone and bleomycin. The overall objective RR was 80% (36% complete response). The mycosis fungoides (MF) RR was 84%, with a median duration of 8.7 months. The pleomorphic-lymphoma RR was higher (100%), but the corresponding response duration was shorter (median: 3 months). No responses were documented in Sézary syndrome. VICOP-B regimen is effective and feasible as first-line chemotherapy in advanced MF, with or without extracutaneous involvement.
Citations
May 22, 2001·The British Journal of Dermatology·J J ScarisbrickR Russell-Jones
Sep 13, 2001·British Journal of Haematology·E OlavarriaR Russell-Jones
Apr 30, 2002·American Journal of Clinical Dermatology·Narin ApisarnthanaraxMadeleine Duvic
Jan 7, 2011·Case Reports in Medicine·Li-Jun XueJi-Hong Yang
Jun 30, 2004·Leukemia & Lymphoma·D A PichardoS T Rosen
Jan 28, 1999·Leukemia & Lymphoma·M T FierroM G Bernengo
Dec 17, 2014·Expert Review of Hematology·Bláithín Moriarty, Sean Whittaker
Dec 15, 2010·Journal of the American Academy of Dermatology·Elise A OlsenMadeleine Duvic
Apr 1, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Franz TrautingerSean Whittaker
Oct 5, 2015·Dermatologic Clinics·Catherine G Chung, Brian Poligone
Aug 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pier Luigi ZinzaniMichele Baccarani
Mar 5, 2004·The British Journal of Dermatology·P QuaglinoM G Bernengo
Oct 18, 2005·The British Journal of Dermatology·T YokoteT Hanafusa
Dec 19, 2018·The British Journal of Dermatology·D GilsonS L Morris
Nov 28, 2020·The Journal of Dermatology·Mikio OhtsukaMakoto Sugaya